Report presents detailed analysis of Asthma and COPD drugs market using Porter’s five forces model. Degree of bargaining power of consumers is expected to be high due to competition among industry leaders for innovative products. Threat of new entrants is high, as the business needs moderately high capital investment.
Asthma and COPD (Chronic Obstructive Pulmonary Disease) are chronic diseases characterized by airway obstruction in the lungs causing respiratory infection and fatigue. COPD is characterized by yellow phlegm in the cough and episodes of cough and wheezing at night are the characteristics of asthma. Asthma and COPD drugs are the drugs that are used to treat symptoms of Asthma and COPD. These medications are generally prescribed by the pharmacists, practitioners, asthma educators, respiratory physicians, practice nurses and allergists. Traditional therapies include anti-inflammatory glucocorticosteroid and inhaled bronchodilator. Use of these therapies results in adverse effects and sometimes may worsen the symptoms of asthma and COPD. Drug treatment of asthma mainly aims at the symptomatic relief and disease modification. Drug treatment also prevents lung damage and reduces inflammation.
The growth of the Asthma and COPD drugs market is driven by the factors such as raised level of pollution and increasing aging population. Advanced therapies of medical cure and rising disposable income are also contributing to the growth of the market. However, high cost of some of the drugs and loss of patents of major Asthma and COPD drugs are the major factors that are hampering the growth of the market. Rising entry of beta-agonists, combinational therapies and inhaled corticosteroids are few of the challenges that Asthma and COPD drugs Market is facing.
Increased awareness about the timely diagnosis, early stage treatment of Asthma and COPD are creating opportunities for the growth of the market. Many companies are adopting CMO (contract manufacturing outsourcing) and focusing on new product development. This shows huge opportunity for the enlargement and expansion of the market.
Asthma and COPD Drug Disease Market Analysis
Asthma and COPD Drug disease market is segmented into asthma drugs and COPD drugs. COPD drugs segment is the largest revenue generating segment due to rise in the aging population and relative rise in the rate of COPD cases compared to asthma.
Asthma and COPD Drug Product Market Analysis
Asthma and COPD Drug product market is segmented into combination therapies, anti- inflammatories, and bronchodilators. Anti- inflammatories can be further segment into monoclonal antibodies, anti- leukotriene and inhaled corticosteroids. Bronchodilators can also be further segmented into anticholonergics, long acting bronchodilators and short acting bronchodilators. Bronchodilators segment is the largest revenue generating segment due to its long- acting bronchodilators drugs that can treat the symptoms of COPD quickly. Long- acting bronchodilators drugs are considered to be the best cure for COPD.
Asthma and COPD Drug Geography Market Analysis
Geographically, Market is segmented into North America, Europe, Asia Pacific and RoW. Asia Pacific is the largest revenue generating segment due to relatively rising smokers and increased exposure to environmental tobacco smoke & combustion of solid fuels.
The key strategies adopted by the companies to expand in the Asthma and COPD drugs market are product expansion, mergers & acquisitions and agreements & collaborations. These strategies would provide efficient products and yield strong performing products that support the market regulations and finally, exhibit better customer satisfaction. Top market players include AstraZeneca, GlaxoSmithKline, Merck, Singulair, Symbicort, and Advair.
High level Analysis
Report presents detailed analysis of Asthma and COPD drugs market using Porter’s five forces model. Degree of bargaining power of consumers is expected to be high due to competition among industry leaders for innovative products. Degree of bargaining power of suppliers is expected to be moderate, due to good number of vendors present in market. Threat of new entrants is high, as the business needs moderately high capital investment.
• Analysis of the Asthma and COPD drugs market on the foundation of range of segments is expounded in the report, and segmental analysis is done to categorize the leading revenue generating segment
• To study the various factors that are enhancing and restraining the development of the market that would help the stakeholders in understanding the market in detail
• Study of SWOT and analysis of the captivating strategies adopted by the players in the market is conducted and that would help in assisting the stakeholders to take actionable decision
• Analysis of the current market scenario, forecasts of the future transition trends and projected revenue of the market through 2013-2020 are expounded in the report; thus, help stakeholders analyze the market
• To find out the recent trends of the Asthma and COPD drugs market and opportunity that would unlock doors for the investors to contribute in the market, which in turn would facilitate in the extension of the strategies
Key Market Segment
Asthma and COPD drugs market is segmented on the basis of disease, product, and geography.
Market by Disease
Market by Product
• Combination Therapies
• Anti- Inflammatories
• Monoclonal Antibodies
• Anti- Leukotriene
• Inhaled Corticosteroids
• Long Acting Bronchodilators
• Short Acting Bronchodolators
Market by Geography
• North America
• Asia Pacific